Adderall® produces increased striatal dopamine release and a prolonged time course compared to amphetamine isomers

@article{Joyce2006AdderallPI,
  title={Adderall{\textregistered} produces increased striatal dopamine release and a prolonged time course compared to amphetamine isomers},
  author={B. Matthew Joyce and Paul E. A. Glaser and Greg A. Gerhardt},
  journal={Psychopharmacology},
  year={2006},
  volume={191},
  pages={669-677}
}
RationaleAdderall® is currently used for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) and is composed of a novel mixture of approximately 24% l-amphetamine and 76% d-amphetamine salts. There are, however, no investigations of the pharmacological effects of this combination in vivo.ObjectivesThe technique of high-speed chronoamperometry using Nafion®-coated single carbon-fiber microelectrodes was used to study amphetamine-evoked dopamine (DA) release produced by Adderall®, d… 

Amphetamine and Methamphetamine Differentially Affect Dopamine Transporters in Vitro and in Vivo*

TLDR
It is demonstrated that METH has a stronger effect on DAT-mediated cell physiology than AMPH, which may contribute to the euphoric and addictive properties of METH compared with AMPH.

Amphetamine Paradoxically Augments Exocytotic Dopamine Release and Phasic Dopamine Signals

TLDR
These findings identify upregulation of exocytotic dopamine release as a key AMPH action in behaving animals and support a unified mechanism of abused drugs to activate phasic dopamine signaling.

Amphetamine, past and present – a pharmacological and clinical perspective

TLDR
The review charts advances in pharmaceutical development from the introduction of once-daily formulations of amphetamine through to lisdexamfetamine, which is the first d-amphetamine prodrug approved for the management of ADHD in children, adolescents and adults.

Attention-Deficit Hyperactivity Disorder

TLDR
The efficacy and safety of five of the more novel long-acting pharmacological treatments recently approved by the FDA for marketing in the US for paediatric ADHD, along with an α2-adrenoceptor agonist in preparation are considered.

Dopamine and Glutamate Dysfunction in a Rodent Model of Attention-Deficit/Hyperactivity Disorder: Implications for Future Neuropharmacology

TLDR
It is discovered that the glutamate system in the FC of the SHR model of ADHD is hyperfunctional, thus raising the possibility that targeting glutamate dysfunction in theFC could lead to the development of novel therapeutics for the treatment of ADHD.

References

SHOWING 1-10 OF 63 REFERENCES

Differential effects of amphetamine isomers on dopamine release in the rat striatum and nucleus accumbens core

TLDR
Data support the hypothesis that amphetamine isomers have different effects on release of DA from nerve endings, and it is possible that l-amphetamine may have unique actions on the DA transporter, which is required for the effects of amphetamine on DA release from nerve terminals.

Amphetamine and Other Weak Bases Act to Promote Reverse Transport of Dopamine in Ventral Midbrain Neurons

TLDR
The weak base mechanism of amphetamine action, in which amphetamine reduces vesicular pH gradients resulting in increased cytoplasmic dopamine that promotes reverse transport, is extended.

Locomotor effects of acute and repeated threshold doses of amphetamine and methylphenidate: relative roles of dopamine and norepinephrine.

  • R. KuczenskiD. Segal
  • Psychology, Biology
    The Journal of pharmacology and experimental therapeutics
  • 2001
TLDR
Evidence is provided that low-dose stimulant administration can result in the development of behavioral sensitization, which is evident in the subsequent behavioral response to the drug.

Intracellular Ca2+ regulates amphetamine-induced dopamine efflux and currents mediated by the human dopamine transporter.

TLDR
It is demonstrated that Amphetamine-induced DAT-mediated currents and substrate efflux require internal Ca(2+) and that amphetamine can stimulate dopamine efflux by regulating cytoplasmic Ca( 2+) levels through its interaction with DAT.

Repeated Cocaine Modifies the Mechanism by which Amphetamine Releases Dopamine

TLDR
It is demonstrated that the psychostimulant-induced enhanced increase in extracellular dopamine in the nucleus accumbens shell of cocaine-pretreated rats arises from the induction of calcium- and CaM-KII-dependent mechanisms.

Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism.

TLDR
Evidence is presented that DAT substrates, including AMPH and DA, cause internalization of human DAT, thereby reducing transport capacity, and acute application of AMPH would reduce DA uptake not only by direct competition for uptake, but also by reducing the available cell-surface DAT.

Amphetamine enantiomer excretion profile following administration of Adderall.

TLDR
Results are the first to describe the excretion of amphetamine following administration of Adderall, a 3:1 mixture of d- and l-enantiomers of Amphetamine salts.

Amphetamine induces dopamine efflux through a dopamine transporter channel.

TLDR
It is reported that AMPH causes DAT-mediated DA efflux by two independent mechanisms: a slow process consistent with an exchange mechanism and a process that results in rapid (millisecond) bursts ofDA efflux through a channel-like mode of DAT.
...